冠心病患者血清2′Ome-miR-486-5p水平较高,且是冠状动脉狭窄程度的影响因素,可作为冠心病患者辅助诊断的生物标志物。 冠心病是最常见的心血管疾病,动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease,ASCVD)的常见类型,指的...
移植过表达miR-486-5p的N-sEV（N-sEVmiR-486-5p）或miR-486-5p敲减的HP-sEV（HP-sEVanti-miR-486-5p）均发现可显著促进梗死区心肌血管新生及心功能恢复。该研究通过心脏组织转录组测序、荧光素酶报告系统、蛋白相互作用等手段进一步发现miR-486-5p通过抑制成纤维细胞基质金属蛋白酶（MMP19）表达，从而减少对胞...
STS通过下调局部肺部囊性纤维化跨膜电导调节因子来保护COPD。STS通过上调来自循环的miR-486-5p来保护COPD,这表明来自局部和循环的各种因素都参与了STS对COPD的保护作用。通过测序显示,在STS治疗的COPD小鼠来源的外泌体中,miR-22-3p、m...
MiR-486-5p
作者还确定了血清miR-486-5p水平与人心力衰竭的关系。综上所述,这些发现表明IgE-FcεR1和miR-486A-5P是治疗心肌纤维化的潜在的新的治疗靶点。
Functionally, miR-486-5p mimics resulted in a significant repression of TNBC cellular viability and colony forming ability. Conclusion miR-486-5p is an immunomodulatory tumor suppressor miRNA acts by alleviating the immunesuppressive profile of TNBC cells. Legal entity responsible for the study German ...
MicroRNA (miR)-486-5p protects against kidney ischemia–reperfusion (IR) injury in mice, although its long-term effects on the vasculature and development of CKD are unknown. We studied whether miR-486-5p would prevent the AKI to CKD transition in rat, and affect vascular function. Methods:...
认为,miR一486—5p是SIRT1的内 源性抑制剂,能诱导人脂肪组织来源的间充质干细胞 (humanadiposetissue—derivedmesenchymalstem cells,hAT—MSCs)复制性衰老,而SIRT1被证实是 miR一486—5p的靶基因。有研究者认为,miR一486 在胃癌中是一新的抑癌miRNA,其靶基因为抗凋亡 ...
认为,miR一486—5p是SIRT1的内 源性抑制剂,能诱导人脂肪组织来源的间充质干细胞 (humanadiposetissue—derivedmesenchymalstem cells,hAT—MSCs)复制性衰老,而SIRT1被证实是 miR一486—5p的靶基因。有研究者认为,miR一486 在胃癌中是一新的抑癌miRNA,其靶基因为抗凋亡 ...